Segal’s Q3 2026 Stop-Loss Trends report, published in July 2026 from a dataset of 225 health plans, puts average specific stop-loss premium increases at 12.7% for plans holding their deductible flat, up from 9.7% in the prior period. That headline understates the underlying pressure. Global stop-loss reinsurance pricing rose 15% in 2026, and the industry loss ratio sits at 85% against a 75% carrier target. Voya, one of the market’s largest stop-loss writers, raised employer rates an average of 24% for January 2026 renewals and reported a Q4 2025 loss ratio of 96% against its own 77-to-80% target. The company’s CEO described the path back to profitability as “a two-year journey.”
The incidence data explains why. Voya’s 2025 paid claims analysis documents stop-loss incidence jumping 37%, from 23.8 to 32.5 per 1,000 covered employees. GLP-1 medications now cost $15,000 to $20,000 per covered employee annually. A single gene therapy claim runs $2 million or more. The stop-loss market grew from $35.4 billion to over $40 billion in 2026, with premium volume outrunning exposure growth, a structural signal that the pricing pressure is not a one-cycle event. Benefits Blake’s reinsurance transmission analysis notes that global reinsurers are describing capacity as selective rather than open, meaning 2027 treaty pricing is unlikely to ease materially regardless of individual plan claims history.
Who It Affects
Self-insured employers negotiating 2027 stop-loss renewals with October 1 or January 1 effective dates, captive managers providing stop-loss coverage to group captive members, and CFOs signing off on IBNR estimates for the retained health plan layer. Plans with more than 500 covered lives that absorbed GLP-1 utilization growth since 2023 without adjusting their specific deductible face the sharpest exposure. Million-dollar-plus claims now affect half of self-insured employers, reshaping what a “shock claim” frequency assumption should look like.
Reserve Mechanism: ECR and Attachment Point Adequacy
For a self-insured employer, the specific deductible (the individual stop-loss attachment point) defines the boundary between claims the plan retains and claims the carrier reimburses. When that boundary has not moved in step with severity trend, the expected claim ratio (ECR) for the retained layer is understated, and the IBNR estimate for the plan is understated with it.
The familiar response to rising stop-loss premiums is to raise the specific deductible to suppress the premium cost. In a normal cycle, that tradeoff is defensible. In the current cycle, it is a reserve adequacy risk. The 15% reinsurance repricing reflects a sustained gap between actual loss experience and carrier targets that will not close in a single contract year. An employer who raises its deductible from $250,000 to $350,000 to offset a 12.7% premium increase is now retaining claims in the $250,000-to-$350,000 corridor at a time when incidence in that band is accelerating. From reviewing January 2026 stop-loss renewal packages for self-funded clients with 500 to 5,000 covered lives, the specific deductible has become the single most contested actuarial negotiation point, with carriers now pricing based on prior claims history in ways that expose plan sponsors who raised their deductible two years ago to a retained-risk corridor they have not fully reserved for.
The IBNR estimate for the retained layer needs to reflect that wider corridor at current severity and incidence levels, not the levels that prevailed when the attachment point was originally set.
What This Means for Your Next Review
Before your 2027 renewal negotiation finalizes, ask your actuary to calculate what your specific deductible represents as a percentage of expected annual claims and whether that ratio has drifted over the past three years. If the attachment point has not moved while GLP-1 utilization and gene therapy incidence have accelerated severity, the premium savings from raising the deductible may be offset by a larger IBNR adjustment that does not show up until claims development catches up.
Stop-loss carriers project the correction cycle to run through 2028 or 2029. For 2027 renewal planning, the 12.7% average increase from Segal’s dataset should be treated as a planning floor, not a ceiling.